Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. In line with this, the FDA has launched the Advancing Real-World Evidence (RWE) Program, aiming to harness the benefits of RWD to support new labelling claims, expand indications for approved medical products, and fulfil post-approval study requirements.
Goals of the Program:
- Identify strategies for creating RWE that satisfies regulatory needs for labelling effectiveness or post-approval study obligations.
- Establish agency protocols for consistent RWE decision-making and shared knowledge.
- Encourage public understanding of RWE’s attributes for informed regulatory choices through public discussions.
Eligibility:
- Sponsors must have a pre-IND or IND number for their medical product
- The RWE proposal should aim at supporting labelling for effectiveness or meeting post-approval study demands
- Both FDA and sponsor must consent to publicly disclose the study design
Selection:
- The FDA welcomes all fitting RWE proposals. Selection is based on data’s suitability, study design quality, regulatory conduct, and diverse data sources and methodologies
Submission Process:
- Semi-annual submission deadlines: 31 March and 30 September, continuing until 31 March 2027
- Sponsors will be told whether their meeting request has been accepted within 45 days post-deadline. Successful applicants can apply for an additional 3 follow-up meetings.
Initial Meeting Request Content – Sponsors must provide:
- Product name
- IND number
- Study purpose (new labelling/post-approval study)
- Proposed indication
- Product development history
- Rationale for RWE approach
- Study design overview
- Non-disclosable design elements and reasons for their omission
- Study design details: objectives, design, eligibility, endpoints, treatment, comparator, concomitant therapies
- Data sources: category, description, validation, linkage, additional data collection.
- Analysis plan: sample size, analytic plan, confounding factors, follow-up period, data handling
- Other factors: study pre-specification, patient data availability, human subject protection
Disclosure Agreement:
Before initial meetings, FDA and sponsors decide on public data disclosure. Certain details, like sponsor name and patient data, are excluded from disclosure. However, unique disclosure considerations are allowed. Participation is voluntary.
In conclusion, the FDA’s Advancing RWE Program offers a structured approach for sponsors to collaborate with the FDA and harness the potential of RWE in label extensions and post market studies.
Real World Evidence (RWE) 201…THE END – A Landscape Analysis of Regional RWE Frameworks – The European Health Data Space and DARWIN-EU
stuart.mccully2023-12-08T14:58:47+00:00December 8, 2023|2023, RWE 201|
RWE 201 - THE END - A Landscape Analysis of Regional RWE Frameworks - The European Health Data Space and DARWIN-EU In our real world evidence (RWE) 201 series [...]
Real World Evidence (RWE) – Event Horizon
stuart.mccully2023-12-08T14:54:21+00:00December 8, 2023|2022, RWE 201|
RWE 201 - RWE Event Horizon The term "event horizon" in the context of pharmaceuticals, particularly when discussing the shift towards real-world evidence (RWE) in regulatory submissions, is metaphorically [...]
Real World Evidence (RWE) 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
stuart.mccully2023-12-08T14:49:27+00:00December 8, 2023|2023, RWE 201|
RWE 201 - Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development Australia has several real-world evidence (RWE) initiatives to support healthcare [...]
Real World Evidence (RWE) 201 – South Korea’s Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development
stuart.mccully2023-12-08T14:39:24+00:00December 8, 2023|2023, RWE 201|
RWE 201 - South Korea's Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development South Korea has several initiatives to support healthcare and drug development using [...]
Real World Evidence (RWE) 201 – Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making
stuart.mccully2023-12-08T14:34:38+00:00December 8, 2023|2023, RWE 201|
RWE 201 - Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making Taiwan has several real-world evidence (RWE) initiatives to support healthcare and drug development. Over the past [...]
Real World Evidence (RWE) 201 – Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development
stuart.mccully2023-12-08T14:31:09+00:00December 8, 2023|2023, RWE 201|
RWE 201 - Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development Japan has several initiatives to support healthcare and drug development using real-world evidence (RWE). [...]
USA | FDA Announces New Advancing RWE Program
Please login to view this page.